malignant hematological diseases ( including acute myeloid leukemia?acute lymphoblastic leukemia, etc.)
Conditions
Interventions
Romiplostim N01 cohort:Romiplostim N01 treatment
rhTPO cohort:rhTPO treatment
Sponsors
The first affiliated hostipal of nanchang university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with malignant hematological diseases who received allo-HSCT(including haploid or HLA-Identical); 2.Weight >= 30kg, regardless of age or gender; 3.ECOG score <= 1; 4.Patients is eligible for follow-up; 5.Patients without serious functional damage of major organs was found in the whole body; 6.Patients voluntarily sign informed consent forms.
Exclusion criteria
Exclusion criteria: 1.Have serious organ dysfunction or disease, such as heart, liver, kidney, pancreas and other serious disease and dysfunction; 2.Patients who cannot tolerate subcutaneous injections of Romiplostim N01 or rhTPO; 3.Any life-threatening disease, medical condition, or organ system dysfunction that the investigator believes could compromise the safety of the subject or put the results of the study at unnecessary risk; 4.Patients who was drug dependent or uncontrolled mental illness or with cognitive disabilities; 5.Joined other similar clinical investigators within 3 months; 6.Other conditions not suitable for inclusion evaluated by the investigator (such as patients who are expected to be unable to adhere to treatment due to financial problems, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the time of platelet engraftment; | — |
Countries
China
Contacts
Public ContactFei Li
The first affiliated hostipal of nanchang university
Outcome results
None listed